# China NMPA Drug Inspection - Hubei Xunda Pharmaceutical Co., Ltd. - safflower

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-xunda-pharmaceutical-co-ltd/c1bfb49f-0786-4cf6-8b91-3514eb4ac28c/
Source feed: China

> China NMPA drug inspection for Hubei Xunda Pharmaceutical Co., Ltd. published January 12, 2017. Drug: safflower. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 5 of 2017 from the State Administration for Market Regulation on the Results of Special Sampling Inspections of Chinese Medicinal Herbs and Prepared Slices
- Company Name: Hubei Xunda Pharmaceutical Co., Ltd.
- Publication Date: 2017-01-12
- Drug Name: safflower
- Inspection Finding: Lemon yellow was detected, indicating a dyeing problem. In addition, some batches of products also had issues with their appearance, identification, impurities, or content determination not meeting the standard requirements.
- Action Taken: We have taken timely and lawful measures to control the products, including sealing and seizing, suspending production and sales, and requiring companies to voluntarily recall their products. We have also filed cases against the relevant companies and units for investigation and punishment.

Company: https://www.globalkeysolutions.net/companies/hubei-xunda-pharmaceutical-co-ltd/2beaa563-e464-473d-8ec1-7a46c02cfc23/